Ester-E Sales Grow at Retail Despite Category Declines; Zila Attributes New Research, Form Differentiation, and Marketing Suppor
May 04 2005 - 6:30AM
Business Wire
Zila, Inc. (Nasdaq:ZILA), the parent company of Zila
Nutraceuticals, Inc., maker of Ester-C(R), announces growing retail
sales for Ester-E(R), its unique, patented form of vitamin E. The
significance of this growth is evident when compared with the
downward trend of the vitamin E category as a whole, and in light
of the recent negative press on vitamin E. According to A.C.
Nielsen (via SPINS), the vitamin E category continues to be down
more than 40 percent versus last year on a dollar basis since a
negative analysis of vitamin E was published last November. In the
past 12-week period ending March 19, 2005, the category was
reported down by 42 percent in Food, Drug, and Mass Merchandisers.
However, for the same period, Ester-E sales increased, up 35
percent on a dollar basis versus the previous 12-week period ending
December 25, 2004. As Ester-E was launched in the summer of 2004,
comparable year ago comparisons are not available. "In a category
that has been reeling due to negative press, there is one form of
vitamin E that is shining - Ester-E," said Ken Vargha, director of
marketing for Zila Nutraceuticals. "We believe that Ester-E is
succeeding because it is a unique form of the vitamin, and we're
investing heavily to help educate consumers about the difference."
The differences between Ester-E and other forms of vitamin E, as
evidenced by previously published in vitro and animal studies,
continue with the most recent animal study. This study, conducted
by Monash University in Australia, found that Ester-E reduced LDL
cholesterol (the "bad" cholesterol) in mice by up to 40 percent.
Ester-E also significantly reduced triglycerides, while regular
vitamin E (d-alpha-tocopheryl acetate) had no effect in this study.
This study, when coupled with previous positive in vitro studies,
suggests Ester-E's potential to benefit cardiovascular health.
Larry Robinson, Ph.D., vice president of scientific affairs for
Zila Nutraceuticals, cited two recent findings on vitamin E - the
HOPE TOO and Johns Hopkins studies - as both mentioning vitamin E's
pro-oxidant potential as a possible reason why large doses of
vitamin E were observed to produce negative results. "While we
question the validity of these studies and continue to believe that
all forms of vitamin E are safe, nevertheless, Ester-E in its
protected form cannot chemically act as a pro-oxidant. Because of
this and the many studies that have been conducted with it, we
believe it is not only safe but also acts differently in the body
than other forms," said Robinson. "The exciting potential of
Ester-E will continue to be tested in our ongoing human clinical
trial with a contract research organization, and our upcoming human
clinical trial at the University of Michigan Medical School." In
the April issue of the American Journal of Clinical Nutrition
(AJCN) fourteen leading safety and antioxidant experts reviewed the
available scientific literature on vitamin E and concluded vitamin
E is safe for the general population at intakes up to 1600 IU
daily. In reviewing the available scientific literature on vitamin
E, the scientists reviewed clinical trials as well as
epidemiological studies in humans, determining there was sufficient
information from human data to support a conclusion of safety. The
review of the scientific literature encompassed 95 references,
including the recent, controversial meta-analysis on vitamin E from
Johns Hopkins University. About Ester-E Ester-E is an advanced form
of vitamin E containing tocopheryl phosphates (or "TP" for short).
Until recently, scientists were unaware of this important source of
vitamin E in the body. Thanks to groundbreaking research, we now
know that TP is present in many foods we eat every day - especially
dairy products. This research suggests that the human body may also
convert other forms of vitamin E into TP in order to protect the
vitamin's antioxidant strength until the body is ready to use it.
Scientists are now able to replicate this natural form of vitamin E
that the body can easily recognize - it is for this reason Ester-E
is considered "body ready." Ester-E is able to preserve vitamin E's
natural health benefits until the body is ready to use it. Visit
www.Ester-E.com for more information about Ester-E and other
premium products. About Zila, Inc. Zila, Inc., headquartered in
Phoenix, is an innovator in preventative healthcare technologies
and products, focusing on enhanced body defense and the detection
of pre-disease states. Zila has three business units: Zila
Biotechnology, a research, development and licensing business
specializing in pre-cancer/cancer detection through its patented
Zila(R) Tolonium Chloride and OraTest(R) technologies. Zila
Pharmaceuticals, marketer of products to promote oral health and
prevent oral disease, including ViziLite(R) oral examination kits,
Peridex(R) prescription periodontal rinse and Zilactin(R) OTC oral
care products. Zila Nutraceuticals, manufacturer and marketer of
Ester-C(R) and Ester-E(R), branded, highly effective forms of
Advanced Protection vitamins C and E. For more information about
Zila, visit www.zila.com. This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based largely on
Zila's expectations or forecasts of future events, can be affected
by inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its
fiscal year ended July 31, 2004, and its Form 10-Q for the quarter
ended January 31, 2005, filed with the Securities and Exchange
Commission.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jul 2023 to Jul 2024